Acute Kidney Injury Due to Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan: A Case Report

被引:0
|
作者
Shima, Hisato [1 ,2 ]
Nishitani, Masaaki [3 ]
Izaki, Hirofumi [4 ]
Minakuchi, Jun [1 ]
机构
[1] Kawashima Hosp, Kidney Dis, Tokushima, Japan
[2] Kamei Hosp, Nephrol & Hypertens, Tokushima, Japan
[3] Kawashima Hosp, Urol, Tokushima, Japan
[4] Tokushima Prefectural Cent Hosp, Urol, Tokushima, Japan
关键词
tolvaptan; nephrolithiasis; transurethral lithotripsy; acute kidney injury; autosomal dominant polycystic kidney disease; CALCULI;
D O I
10.7759/cureus.62597
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 61 -year -old asymptomatic female with autosomal dominant polycystic kidney disease (ADPKD) on tolvaptan therapy was hospitalized for acute kidney injury (AKI). Nephrolithiasis had already been diagnosed; however, the patient had not undergone any interventions. She also presented with hyponatremia possibly caused by overhydration. Because the estimated glomerular filtration rate (eGFR) decline was significantly higher than the predicted rate, we considered a possible case of postrenal AKI and examined computed tomography (CT), which revealed left hydronephrosis with a 9.4 -mm ureteric stone at the level of L3/L4. We restricted fluid intake, which resulted in an increase in sodium levels. She was treated with transurethral lithotripsy (TUL) twice, which successfully improved her kidney function. Although the serum sodium levels increase because of aquaresis in almost all patients treated with tolvaptan, our case was unique in that the patient presented with hyponatremia. We should pay more attention to the periodical follow-up of nephrolithiasis in addition to the increase in total kidney volume and decide the appropriate time to treat nephrolithiasis depending on the case. We should also keep in mind that ADPKD patients have a high frequency of nephrolithiasis and, even if asymptomatic, investigate urinary tract obstruction and hydronephrosis in case of AKI.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
    Hiroko Iijima
    Toshifumi Tada
    Mariko Hashimoto
    Takashi Nishimura
    Masato Kiriki
    Akiko Higashiura
    Aya Iwasaki
    Michino Honda
    Yasuyuki Nagasawa
    Koichiro Yamakado
    Journal of Medical Ultrasonics, 2023, 50 : 81 - 87
  • [22] Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease
    Masahiko Oguro
    Yuta Kogure
    Junichi Hoshino
    Yoshifumi Ubara
    Hiroki Mizuno
    Akinari Sekine
    Masahiro Kawada
    Keiichi Sumida
    Rikako Hiramatsu
    Eiko Hasegawa
    Masayuki Yamanouchi
    Noriko Hayami
    Tatsuya Suwabe
    Naoki Sawa
    Kenmei Takaichi
    Journal of Nephrology, 2018, 31 : 961 - 966
  • [23] Autosomal dominant polycystic kidney disease with ectopic unilateral multicystic kidney: a case report
    Yaw Amoah
    Mathew Yamoah Kyei
    James Edward Mensah
    Bridget Palm
    Henry Kwasi Adrah
    Isaac Asiedu
    Journal of Medical Case Reports, 18
  • [24] Disseminated kidney tuberculosis complicating autosomal dominant polycystic kidney disease: a case report
    Takeshita, Hideki
    Amemiya, Morimasa
    Chiba, Koji
    Urushibara, Masayasu
    Satoh, Jun-ichi
    Noro, Akira
    CLINICAL NEPHROLOGY, 2012, 77 (03) : 242 - 245
  • [25] Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease
    Oguro, Masahiko
    Kogure, Yuta
    Hoshino, Junichi
    Ubara, Yoshifumi
    Mizuno, Hiroki
    Sekine, Akinari
    Kawada, Masahiro
    Sumida, Keiichi
    Hiramatsu, Rikako
    Hasegawa, Eiko
    Yamanouchi, Masayuki
    Hayami, Noriko
    Suwabe, Tatsuya
    Sawa, Naoki
    Takaichi, Kenmei
    JOURNAL OF NEPHROLOGY, 2018, 31 (06) : 961 - 966
  • [26] Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
    Iijima, Hiroko
    Tada, Toshifumi
    Hashimoto, Mariko
    Nishimura, Takashi
    Kiriki, Masato
    Higashiura, Akiko
    Iwasaki, Aya
    Honda, Michino
    Nagasawa, Yasuyuki
    Yamakado, Koichiro
    JOURNAL OF MEDICAL ULTRASONICS, 2023, 50 (01) : 81 - 87
  • [27] Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
    Mueller, Roman-Ulrich
    Haas, Christian S.
    Sayer, John A.
    CLINICAL KIDNEY JOURNAL, 2018, 11 (01) : 62 - 69
  • [28] Autosomal dominant polycystic kidney disease with ectopic unilateral multicystic kidney: a case report
    Amoah, Yaw
    Kyei, Mathew Yamoah
    Mensah, James Edward
    Palm, Bridget
    Adrah, Henry Kwasi
    Asiedu, Isaac
    JOURNAL OF MEDICAL CASE REPORTS, 2024, 18 (01)
  • [29] Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
    Edwards, Marie E.
    Chebib, Fouad T.
    Irazabal, Maria V.
    Ofstie, Troy G.
    Bungum, Lisa A.
    Metzger, Andrew J.
    Senum, Sarah R.
    Hogan, Marie C.
    El-Zoghby, Ziad M.
    Kline, Timothy L.
    Harris, Peter C.
    Czerwiec, Frank S.
    Torres, Vicente E.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 13 (08): : 1153 - 1161
  • [30] Acute pulmonary thromboembolism occurring during treatment with tolvaptan in a patient with autosomal-dominant polycystic kidney disease
    Katsuhiko Morimoto
    Yasuhiro Akai
    Masaru Matsui
    Hiroki Yano
    Miho Tagawa
    Ken-ichi Samejima
    Yoshihiko Saito
    CEN Case Reports, 2017, 6 (1) : 61 - 65